BACKGROUND: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the efficacy of UPA to obtain remission or low disease activity (LDA) in a series of UPA patients in patients with RA after 6 and 12 months of treatment in a real-world setting. METHODS: A series of 111 consecutive patients treated with UPA in 23 rheumatology centers were enrolled. Personal history, treatment history and disease activity at baseline, after 6 and 12 months were recorded. Intention-to-treat (ITT) and per-protocol (PP) analyses assessed achievement of remission or LDA or defined as DAS28 <2.6 and ≤3.2, respectively. Logistic regression analysis examined the role of several independent factors on the reduction of disease activity after 6 months of treatment. RESULTS: Of the initial group of 111 subjects at baseline, 86 and 29 participants completed clinical assessments at 6 and 12 months. According to ITT analysis, the rates of remission and LDA were 18% and 18% at 6 months and 31.5% and 12.5% at 12 months, respectively. PP analysis showed higher rates of remission and LDA at 6 (23.3% and 19.8%) and 12 months (55.2% and 20.7%). Results of multivariate logistic regression analysis indicated that a low DAS28 score (P=0.045) was the only predictor of achieving remission at 6 months. None of the baseline factors predicted remission/ LDA at 6 months. CONCLUSIONS: RA patients treated with UPA achieved a significant rate of disease remission or LDA in a real-world setting. The 6-month response was found to depend only on the baseline value of DAS28, while it was not influenced by other factors such as disease duration, line of treatment or concomitant therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or corticosteroids. (Cite this article as: Lo Gullo A, Parisi S, Becciolini A, Paroli M, Bravi E, Andracco R, et al. Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis. Minerva Med 2024;115:430-8. DOI: 10.23736/S0026-4806.24.09409-6)
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis / Lo Gullo, A.; Parisi, S.; Becciolini, A.; Paroli, M.; Bravi, E.; Andracco, R.; Nucera, V.; Ometto, F.; Lumetti, F.; Farina, A.; Del Medico, P.; Colina, M.; Ravagnani, V.; Scolieri, P.; Larosa, M.; Priora, M.; Visalli, E.; Addimanda, O.; Vitetta, R.; Volpe, A.; Bezzi, A.; Girelli, F.; Molica Colella, B.; Caccavale, R.; Di Donato, E.; Adorni, G.; Santilli, D.; Lucchini, G.; Arrigoni, E.; Plate, I.; Mansueto, N.; Ianniello, A.; Fusaro, E.; Ditto, M. C.; Bruzzese, V.; Camellino, D.; Bianchi, G.; Serale, F.; Foti, R.; Amato, G.; de Lucia, F.; Dal Bosco, Y.; Foti, R.; Reta, M.; Fiorenza, A.; Rovera, G.; Marchetta, A.; Focherini, M. C.; Mascella, F.; Bernardi, S.; Sandri, G.; Giuggioli, D.; Salvarani, C.; de Andres, M. I.; Franchina, V.; Molica Colella, F.; Ferrero, G.; Ariani, A.. - In: MINERVA MEDICA. - ISSN 0026-4806. - 115:4(2024), pp. 430-438. [10.23736/S0026-4806.24.09409-6]
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis
Lumetti F.;Sandri G.;Giuggioli D.;Salvarani C.;
2024
Abstract
BACKGROUND: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the efficacy of UPA to obtain remission or low disease activity (LDA) in a series of UPA patients in patients with RA after 6 and 12 months of treatment in a real-world setting. METHODS: A series of 111 consecutive patients treated with UPA in 23 rheumatology centers were enrolled. Personal history, treatment history and disease activity at baseline, after 6 and 12 months were recorded. Intention-to-treat (ITT) and per-protocol (PP) analyses assessed achievement of remission or LDA or defined as DAS28 <2.6 and ≤3.2, respectively. Logistic regression analysis examined the role of several independent factors on the reduction of disease activity after 6 months of treatment. RESULTS: Of the initial group of 111 subjects at baseline, 86 and 29 participants completed clinical assessments at 6 and 12 months. According to ITT analysis, the rates of remission and LDA were 18% and 18% at 6 months and 31.5% and 12.5% at 12 months, respectively. PP analysis showed higher rates of remission and LDA at 6 (23.3% and 19.8%) and 12 months (55.2% and 20.7%). Results of multivariate logistic regression analysis indicated that a low DAS28 score (P=0.045) was the only predictor of achieving remission at 6 months. None of the baseline factors predicted remission/ LDA at 6 months. CONCLUSIONS: RA patients treated with UPA achieved a significant rate of disease remission or LDA in a real-world setting. The 6-month response was found to depend only on the baseline value of DAS28, while it was not influenced by other factors such as disease duration, line of treatment or concomitant therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or corticosteroids. (Cite this article as: Lo Gullo A, Parisi S, Becciolini A, Paroli M, Bravi E, Andracco R, et al. Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis. Minerva Med 2024;115:430-8. DOI: 10.23736/S0026-4806.24.09409-6)
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
